Showing 5401-5410 of 7316 results for "".
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which incl
- Cutera CEO, Executive Chairman Axedhttps://practicaldermatology.com/news/shake-up-at-cutera-shareholder-ceo-look-to-reconstitute-board/2461654/Cutera, Inc. has fired CEO David Mowry and Executive Chairman Daniel Plants for alleged violations of their employment contracts. Sheila Hopkins has been appointed as interim CEO and the search for a permanent replacement is underway. Plants and Mowry called for a Sp
- Dr. Susan C. Taylor Elected 2025 AAD Presidenthttps://practicaldermatology.com/news/dr-susan-c-taylor-elected-2025-aad-president/2461653/Susan C. Taylor, MD, FAAD is the American Academy of Dermatology’s president-elect. She will be installed in March 2024 and hold the office of president for one year beginning in March 2025. Dr. Taylor previously served as AAD Vice President from 2020 – 2021.
- Dr. James G. Krueger Joins ASA’s Board of Directorshttps://practicaldermatology.com/news/dr-james-g-krueger-joins-asas-board-of-directors/2461651/James G. Krueger, MD, PhD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Krueger is the David Martin Carter Professor in Clinical Investigation and Head of the Laboratory for Investigative Dermatology at The Rockefeller University in&
- News You Can Use: BI Receives Permanent J-Code (J1747) for SPEVIGO Injectionhttps://practicaldermatology.com/news/news-you-can-use-bi-receives-permanent-j-code-j1747-for-spevigo-injection/2461649/The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-code (J1747) for Boehringer Ingelheim’s SPEVIGO (spesolimab-sbzo) Injection, indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. The J-code for SPEVIGO became eff
- Millennials, Gen Xers Not Well-Schooled on Skin Cancer Preventionhttps://practicaldermatology.com/news/millennials-gen-xers-not-well-schooled-on-skin-cancer-prevention/2461648/Millennials and Gen Xers are racked with sun regrets, a new survey shows. Just 19% of millennials and Gen Xers wear sunscreen all year, 35% used a tanning bed, and 46% regretted how long they stayed out in the sun when they were younger. This is why
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arth
- It's Official: April Is the Coolest Month of the Yearhttps://practicaldermatology.com/news/its-official-april-is-the-coolest-month-of-the-year/2461642/April 2023 marks the first-ever CoolMonth, according to Allergan Aesthetics, an AbbVie company and the parent company of CoolSculpting Elite. Why April? A survey revealed 85% of people have a season in which they begin to think more about getting rid of stubborn body fat
- Researchers Discover Anti-Aging Potential in an Invasive Weedhttps://practicaldermatology.com/news/researchers-discover-anti-aging-potential-in-an-invasive-weed/2461638/The fruit of the cocklebur plant, which grows worldwide and is often considered a noxious weed, has antioxidant and anti-inflammatory components that could make it useful as a skin protectant, according to new research
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was